Literature DB >> 11134523

A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.

M Aoki1, E Blazek, P K Vogt.   

Abstract

The oncoproteins P3k (homolog of the catalytic subunit of class IA phosphoinositide 3-kinase) and Akt (protein kinase B) induce oncogenic transformation of chicken embryo fibroblasts. The transformed cells show constitutive phosphorylation of the positive regulator of translation p70S6 kinase (S6K) and of the eukaryotic initiation factor 4E-BP1 binding protein (4E-BP1), a negative regulator of translation. Phosphorylation activates S6K and inactivates 4E-BP1. A mutant of Akt that retains kinase activity but does not induce phosphorylation of S6K or of 4E-BP1 fails to transform chicken embryo fibroblasts, suggesting a correlation between the oncogenicity of Akt and phosphorylation of S6K and 4E-BP1. The macrolide antibiotic rapamycin effectively blocks oncogenic transformation induced by either P3k or Akt but does not reduce the transforming activity of 11 other oncoproteins. Rapamycin inhibits the kinase mTOR, an important regulator of translation, and this inhibition requires binding of the antibiotic to the immunophilin FKBP12. Displacement of rapamycin from FKBP12 relieves the inhibition of mTOR and also restores P3k-induced transformation. These data are in accord with the hypothesis that transformation by P3k or Akt involves intervention in translational controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134523      PMCID: PMC14557          DOI: 10.1073/pnas.98.1.136

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  89 in total

1.  Cell-free translation of avian erythroblastosis virus RNA yields two specific and distinct proteins with molecular weights of 75,000 and 40,000.

Authors:  M M Lai; J C Neil; P K Vogt
Journal:  Virology       Date:  1980-01-30       Impact factor: 3.616

2.  The putative transforming protein of S13 avian erythroblastosis virus is a transmembrane glycoprotein with an associated protein kinase activity.

Authors:  M J Hayman; G Kitchener; P K Vogt; H Beug
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

3.  Characteristics of two new avian tumor virus subgroups.

Authors:  R G Duff; P K Vogt
Journal:  Virology       Date:  1969-09       Impact factor: 3.616

4.  Evidence for three classes of avian sarcoma viruses: comparison of the transformation-specific proteins of PRCII, Y73, and Fujinami viruses.

Authors:  J C Neil; J F Delamarter; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

5.  Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.

Authors:  C J Kuo; J Chung; D F Fiorentino; W M Flanagan; J Blenis; G R Crabtree
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

6.  Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells.

Authors:  N Terada; J J Lucas; A Szepesi; R A Franklin; K Takase; E W Gelfand
Journal:  Biochem Biophys Res Commun       Date:  1992-08-14       Impact factor: 3.575

7.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.

Authors:  D J Price; J R Grove; V Calvo; J Avruch; B E Bierer
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

8.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

9.  Avian sarcoma virus Y73 genome sequence and structural similarity of its transforming gene product to that of Rous sarcoma virus.

Authors:  N Kitamura; A Kitamura; K Toyoshima; Y Hirayama; M Yoshida
Journal:  Nature       Date:  1982-05-20       Impact factor: 49.962

10.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases.

Authors:  J Chung; C J Kuo; G R Crabtree; J Blenis
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

View more
  98 in total

1.  Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Authors:  G B Mills; Y Lu; E C Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Translational control of SCL-isoform expression in hematopoietic lineage choice.

Authors:  Cornelis F Calkhoven; Christine Muller; Richard Martin; Goradz Krosl; Hubertus Pietsch; Trang Hoang; Achim Leutz
Journal:  Genes Dev       Date:  2003-04-15       Impact factor: 11.361

3.  Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein.

Authors:  Kristopher K Frese; Siu Sylvia Lee; Darby L Thomas; Isabel J Latorre; Robert S Weiss; Britt A Glaunsinger; Ronald T Javier
Journal:  Oncogene       Date:  2003-02-06       Impact factor: 9.867

4.  Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins.

Authors:  Masahiro Aoki; Hao Jiang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

5.  mTOR regulates cell survival after etoposide treatment in primary AML cells.

Authors:  Qing Xu; James E Thompson; Martin Carroll
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

6.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis.

Authors:  Akihiro Oguro; Takashi Ohtsu; Yuri V Svitkin; Nahum Sonenberg; Yoshikazu Nakamura
Journal:  RNA       Date:  2003-04       Impact factor: 4.942

8.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

9.  Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Authors:  Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

10.  Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Authors:  Jingxiang Huang; Shulin Wu; Chin-Lee Wu; Brendan D Manning
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.